VTE treatment and prophylaxis

5.0(1)
studied byStudied by 1 person
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
Card Sorting

1/54

encourage image

There's no tags or description

Looks like no tags are added yet.

Study Analytics
Name
Mastery
Learn
Test
Matching
Spaced

No study sessions yet.

55 Terms

1
New cards

when do we use antiplatelets?

for arterial clots from things such as: CAD, PAD, and strokes

2
New cards

when do we use anticoagulants?

for venous clots such as: DTV and PE

3
New cards

VTE prophylaxis treatment goals

Prevent VTE from occurring in patients at high risk (usually only hospitalized patients)

4
New cards

VTE prophylaxis treatment:

Low dose anticoagulant AND/OR mechanical prophylaxis

5
New cards

How is risk of VTE development determined/assessed in hospitalized patients?

With a PADUA score (looking at risk factors)

6
New cards

What does a PADUA score of < 4 mean?

Low risk of VTE - generally does not require thromboprophylaxis

7
New cards

What does a PADUA score of > 4 mean?

Thromboprophylaxis is recommended for non-pregnant patients without contraindications (major bleeding, low platelets) who are > 18 years

8
New cards

T/F: A PADUA risk score is only applicable to non-hospitalized patients

FALSE (only for inpatients)

9
New cards

What is the magic number for VTE prophylaxis from PADUA score?

4!!!

10
New cards

What things are listed as risk factors for a PADUA score?

active cancer, previous VTE, reduced mobility, known genetic hypercoagulable condition, recent trauma/surgery (within 1 month), >= 70 years, cardiac or respiratory failure, acute MI or ischemic stroke, acute infection or rheumatologic disorder, obesity (BMI >= 30), hormonal treatment

11
New cards

Non-pharmacological treatments for VTE prophylaxis

ambulation, graduated compression stockings, sequential compression devices (SCDs), Inferior Vena Cava Filter

12
New cards

heparin SQ dose for VTE prophylaxis

5,000 units Q8-12H

13
New cards

heparin SQ dose for VTE prophylaxis in patients with BMI >= 40 kg/m2?

consider 7,500 units every 8-12 hours

14
New cards

enoxaparin SQ dose for VTE prophylaxis

30 units BID or 40 units daily

15
New cards

fondaparinux SQ dose for VTE prophylaxis

2.5 mg daily

16
New cards

rivaroxaban oral dosing for VTE prophylaxis

10 mg daily

17
New cards

apixaban oral dosing for VTE prophylaxis

2.5 mg BID

18
New cards

dabigatran oral dosing for VTE prophylaxis

220 mg daily

19
New cards

which anticoagulants can be used for orthopedic surgery VTE prophylaxis?

rivaroxaban, apixaban, and dabigatran

20
New cards

T/F: routine pharmacologic thromboprophylaxis should be offered to all outpatients with cancer?

False

21
New cards

If a high-risk outpatient with cancer and a Khorana score >= 2, can they be offered prophylaxis treatment?

Yes, they may be offered thromboprophylaxis with apixaban, rivaroxaban, and LMWH, provided there are no significant risk factors for bleeding and no drug interactions

22
New cards

What can patients with multiple myeloma receiving thalidomide or lenalidomide-based regimens with chemotherapy and/or dexamethasone be offered for VTE prophylaxis?

should be offered pharmacologic thromboprophylaxis with either aspirin or LMWH for lower-risk patients and LMWH for higher-risk patients

23
New cards

treatment for patients with VTE and no cancer

dabigatran, rivaroxaban, apixaban, or edoxaban over vitamin K antagonist (VKA) therapy

24
New cards

treatment for patients with VTE, no cancer, and were not treated with dabigatran, rivaroxaban, apixaban, or dabigatran?

VKA therapy over LMWH

25
New cards

Treatment for patients with unprovoked proximal DVT or PE who are stopping anticoagulant therapy and do not have a contraindication to aspirin

give aspirin to prevent recurrent VTE

26
New cards

Duration of treatment for patients with proximal DVT or PE?

3 months of anticoagulant therapy

27
New cards

duration of treatment with an unprovoked VTE and a low-moderate bleeding risk

extended anticoagulant therapy (no scheduled stop date)

28
New cards

duration of treatment with an unprovoked VTE and a high bleeding risk

3 months of anticoagulant therapy

29
New cards

duration of treatment for patients with DVT of the leg or PE and active cancer

extended anticoagulant therapy (no scheduled stop date)

30
New cards

What is considered low bleed risk?

Patients that have 0 bleed risk factors (risk factors will be given to us!!)

31
New cards

what is considered moderate bleed risk?

Patients that have 1 bleed risk factor (risk factors will be given to us!!)

32
New cards

what is considered high bleed risk?

Patients that have >=2 bleed risk factors (risk factors will be given to us!!)

33
New cards

treatment for patients with acute isolated distal DVT of the leg?

Get distal imaging of the deep veins for 2 weeks, unless there are severe symptoms or risk factors for extension, then it is suggested to give an anticoagulant

34
New cards

treatment for patients with managed anticoagulation

recommended to use the same anticoagulation as for patients with acute proximal DVT

35
New cards

treatment for patients with acute isolated distal DVT of the leg who are managed with serial imaging

no anticoagulation if the thrombus does not extend - suggest anticoagulation if the thrombus extends

36
New cards

initial anticoagulation treatment in cancer patients with DVT

May involve LMWH, UFH, fondaparinux, rivaroxaban, or apixaban.

37
New cards

initial parenteral anticoagulation treatment in cancer patients with DVT

LMWH is preferred over UFH for the initial 5 to 10 days

38
New cards

long-term anticoagulation treatment for cancer patients with DVT

LMWH, edoxaban, or rivaroxaban for at least 6 months due to improved efficacy over VKAs (there is an increase in major bleeding risk with DOACs, particularly in GI and potentially genitourinary malignancies

39
New cards

can anticoagulation treatment be offered to cancer patients with VT past initial 6 months?

they should be offered to select patients with active cancer, such as those with metastatic disease or those receiving chemotherapy

40
New cards

PE acute treatment for low-risk classified patients?

therapeutic anticoagulation

41
New cards

PE acute treatment for intermediate-risk classified patients?

anticoagulation, thrombectomy or catheter-directed thrombolytics, then therapeutic anticoagulation

42
New cards

PE acute treatment for high-risk classified patients?

IV thrombolytics then therapeutic anticoagulation

43
New cards

T/F: some patients with PE and high-risk will get catheter directed thrombolytics and some patients with intermediate risk will get systemic thrombolytics

True

44
New cards

How do thrombolytics work?

they activate plasminogen into plasmin which degrades fibrin clots!

45
New cards

which thrombolytic is fibrin specific?

Tenecteplase (specific to clot bound fibrin)

46
New cards

which thrombolytic is non-specific ?

Alteplase

47
New cards

half-life of alteplase

5 minutes

48
New cards

Half-life of tenecteplase

90-130 minutes

49
New cards

dosing administration of alteplase

bolus followed by infusion

50
New cards

dosing administration of tenecteplase

1 bolus

51
New cards

What are catheter directed thrombolytics (CDT)?

A catheter is inserted into the clot and the holes in the catheter deliver medications that break up the clot

52
New cards

which medications are used in CDT?

heparin and alteplase

53
New cards

Types of CDT

Unifuse without ultrasound and EKOS with ultrasound

54
New cards

what does EKOS stand for

stands for EkoSonic Endovascular System

55
New cards

what is EKOS?

a device to deliver catheter directed thrombolytics + sound waves and may be more efficient at breaking up clots than CDT alone (without ultrasound)